{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:16:00Z","timestamp":1762157760995},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00432-017-2402-x","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T08:59:02Z","timestamp":1490950742000},"page":"1585-1596","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis"],"prefix":"10.1007","volume":"143","author":[{"given":"Francis J.","family":"Giles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljubomir","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Haenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/sj.leu.2403042","volume":"17","author":"U Berger","year":"2003","unstructured":"Berger U et al (2003) Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 17:1820\u20131826. doi: 10.1038\/sj.leu.2403042","journal-title":"Leukemia"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","volume":"84","author":"M Breccia","year":"2012","unstructured":"Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84:93\u2013100. doi: 10.1016\/j.critrevonc.2012.01.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"2402_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F et al (2015) Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol 26:185\u2013192. doi: 10.1093\/annonc\/mdu490","journal-title":"Ann Oncol"},{"key":"2402_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3324\/haematol.2016.144949","volume":"101","author":"F Castagnetti","year":"2016","unstructured":"Castagnetti F et al (2016) Nilotinib 300\u00a0mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica 101:1200\u20131207. doi: 10.3324\/haematol.2016.144949","journal-title":"Haematologica"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J Cortes","year":"2003","unstructured":"Cortes J et al (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98:1105\u20131113. doi: 10.1002\/cncr.11629","journal-title":"Cancer"},{"key":"2402_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G et al (2014) Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica 99:458\u2013464. doi: 10.3324\/haematol.2013.095158","journal-title":"Haematologica"},{"key":"2402_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G et al (2017) Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35:298\u2013305. doi: 10.1200\/JCO.2016.68.2914","journal-title":"J Clin Oncol"},{"key":"2402_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024\u20131029. doi: 10.1002\/ajh.23560","journal-title":"Am J Hematol"},{"key":"2402_CR9","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 117:5591\u20135599. doi: 10.1182\/blood-2010-12-324228","journal-title":"Blood"},{"key":"2402_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423. doi: 10.1200\/JCO.2013.49.9020","journal-title":"J Clin Oncol"},{"key":"2402_CR11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061. doi: 10.1038\/leu.2009.38","journal-title":"Leukemia"},{"key":"2402_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A et al (2016a) Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 30:57\u201364. doi: 10.1038\/leu.2015.270","journal-title":"Leukemia"},{"key":"2402_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A et al (2016b) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. doi: 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"2402_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128:17\u201323. doi: 10.1182\/blood-2016-01-694265","journal-title":"Blood"},{"key":"2402_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP et al (2014) Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 124:729\u2013736. doi: 10.1182\/blood-2013-12-544015","journal-title":"Blood"},{"key":"2402_CR16","first-page":"65","volume":"101","author":"TP Hughes","year":"2016","unstructured":"Hughes TP et al (2016) Results from enestop: treatment-free remission (Tfr) following switch to nilotinib (Nil) in patients (Pts) with chronic myeloid leukemia in chronic phase (Cml-Cp). Haematologica 101:65\u201365","journal-title":"Haematologica"},{"key":"2402_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L et al (2014) Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 93:71\u201380. doi: 10.1007\/s00277-013-1937-4","journal-title":"Ann Hematol"},{"key":"2402_CR18","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00007611-198710000-00007","volume":"80","author":"HM Kantarjian","year":"1987","unstructured":"Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ (1987) Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J 80:1228\u20131232","journal-title":"South Med J"},{"key":"2402_CR19","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM et al (2006) Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108:1835\u20131840. doi: 10.1182\/blood-2006-02-004325","journal-title":"Blood"},{"key":"2402_CR20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood.V116.21.1401.1401","volume":"116","author":"HJ Khoury","year":"2010","unstructured":"Khoury HJ et al (2010) Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. Blood 116:1401\u20131401","journal-title":"Blood"},{"key":"2402_CR21","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood-2011-08-369017","volume":"118","author":"RA Larson","year":"2011","unstructured":"Larson RA et al (2011) Nilotinib shows safety and efficacy in older patients (\u226565 years) with newly diagnosed chronic myeloid leukemia in chronic phase comparable with that in younger patients with chronic myeloid leukemia in chronic phase: results from ENESTnd. Blood 118:1608\u20131609","journal-title":"Blood"},{"key":"2402_CR22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1182\/blood.V114.22.1272.1272","volume":"114","author":"PD le Coutre","year":"2009","unstructured":"le Coutre PD et al (2009) Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study. Blood 114:1272\u20131273","journal-title":"Blood"},{"key":"2402_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE et al (2016) Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101:717\u2013723. doi: 10.3324\/haematol.2015.139899","journal-title":"Haematologica"},{"key":"2402_CR24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V112.11.3233.3233","volume":"112","author":"JH Lipton","year":"2008","unstructured":"Lipton JH, le Coutre PD, Wang J, Yang M, Szczudlo T, Giles F (2008) Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood 112:1110\u20131110","journal-title":"Blood"},{"key":"2402_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju N et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97:1029\u20131035. doi: 10.3324\/haematol.2011.056721","journal-title":"Haematologica"},{"key":"2402_CR26","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00277-014-2041-0","volume":"93","author":"U Proetel","year":"2014","unstructured":"Proetel U et al (2014) Older patients with chronic myeloid leukemia (\u226565 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93:1167\u20131176. doi: 10.1007\/s00277-014-2041-0","journal-title":"Ann Hematol"},{"key":"2402_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2014.342","volume":"29","author":"D Rea","year":"2015","unstructured":"Rea D et al (2015) Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia 29:1206\u20131209. doi: 10.1038\/leu.2014.342","journal-title":"Leukemia"},{"key":"2402_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/leu.2008.245","volume":"23","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23:602\u2013604. doi: 10.1038\/leu.2008.245","journal-title":"Leukemia"},{"key":"2402_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","volume":"92","author":"G Rosti","year":"2007","unstructured":"Rosti G et al (2007) Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. Haematologica 92:101\u2013105","journal-title":"Haematologica"},{"key":"2402_CR30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3324\/haematol.2016.143818","volume":"101","author":"G Saglio","year":"2016","unstructured":"Saglio G et al (2016) Results from ENESTfreedom: treatment-free remission (Tfr) following frontline nilotinib (Nil) in patients (Pts) with chronic myeloid leukemia in chronic phase (Cml-Cp). Haematologica 101:240\u2013241","journal-title":"Haematologica"},{"key":"2402_CR31","first-page":"1517","volume":"94","author":"RT Silver","year":"1999","unstructured":"Silver RT et al (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517\u20131536","journal-title":"Blood"},{"key":"2402_CR32","unstructured":"Tasigna [package insert] (2015) Novartis Pharmaceuticals Corporation, NJ, East Hanover"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T18:54:21Z","timestamp":1601837661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2402-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,31]]}}}